leadf
logo-loader
viewZelira Therapeutics Ltd

Zelira Therapeutics in exclusive licensing deal with Alternative Solutions for distribution of HOPE™ products in Washington DC

Under the terms of the licensing agreement, Zelira will receive an upfront fee and ongoing royalties from HOPE™ product sales in Washington DC. 

Zelira Therapeutics Ltd - Zelira Therapeutics in exclusive licensing deal with Alternative Solutions for distribution of Hope products in Washington DC
Alternative Solutions will commercialize Zelira’s HOPE™ products for sale in the second quarter of 2021

Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) has entered into a binding licensing agreement with Alternative Solutions LLC to manufacture and distribute Zelira’s HOPE™ products in the Washington DC approved medical cannabis market. 

Alternative Solutions will commercialise Zelira’s HOPE™ products for sale in the second quarter of 2021. 

Under the terms of the licensing agreement, Zelira will receive an upfront fee and ongoing royalties from HOPE™ product sales in Washington DC. 

Gateway state with over 24 million visitors

Zelira chief executive officer and managing director USA Dr Oludare Odumosu said: "Our partnership with Alternative Solution, a leader in the Washington DC market, is a strategic move in line with our mission of working with market leaders in approved markets to expand access to HOPE™ across the USA.

“We are particularly excited about this partnership because Washington DC is a gateway state with over 24 million visitors passing through the US capital in a year.

“Washington DC’s reciprocity is a strategic move that allows approved patients from 32 states to legally access HOPE™ in DC.”

Legal, regulated medical cannabis program

Alternative Solutions chief executive officer Matt Lawson-Baker added: “Alternative Solutions is thrilled to be partnering with Zelira to bring the HOPE™ product line to the Washington DC medical cannabis market.

“Providing access to this medicine in the nation’s capital will give many families and patients the treatment they deserve through a legal regulated medical cannabis program.”

Focussed on distribution expansion

Washington DC has reciprocity with 32 other states in the US, with approved medical cannabis programs.

This expands access to patients registered in all the 32 states, as they can legally purchase medical cannabis products at an approved dispensary in Washington DC.

Zelira previously licensed HOPE™ in Pennsylvania to Ilera Healthcare LLC, which holds the licence for that state and in Louisiana to Advanced Biomedics LLC.

Zelira remains focused on expanding the distribution of HOPE™ through licensing agreements in each approved market across the US next year, as the COVID-19 pandemic gets under control.

Alternative Solutions

Alternative Solutions is one of eight current licence holders for the cultivation, processing and distribution of cannabis within the District of Columbia.

The company is licensed to distribute medical cannabis products to all seven licensed MMJ dispensaries within the district.

Operational since 2015, Alternative Solutions focuses on providing a consistent supply of premium products to all licensed dispensaries in DC.

Quick facts: Zelira Therapeutics Ltd

Price: 0.077 AUD

ASX:ZLD
Market: ASX
Market Cap: $91.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Zelira Therapeutics sees 'multiple shots on goal' with a number of revenue...

Zelira Therapeutics Ltd’s (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) deputy chairman Harry Karelis speaks to Proactive's Andrew Scott soon after announcing a strategic consolidation of its operations which sees leadership of the company transfer to the US-based team, with Dr Oludare Odumosu assuming the...

17 hours, 39 minutes ago

2 min read